Has Tinatin Chabrashvili, MD received payments from drug or device companies?

Yes. Drug and device makers reported $38,720 in general payments to Tinatin Chabrashvili, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tinatin Chabrashvili, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tinatin Chabrashvili, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tinatin Chabrashvili, MD

Radiation Oncology · Philadelphia, PANPI 1235316662

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,695 of the $38,720 with a category attached, or 61.2%. Eisai Inc. accounts for 96.5% of it on its own, with 12 other manufacturers making up the rest. Among radiation oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,720in general payments, 2019–2025

Across 92 payments — averaging $420.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eisai Inc.$37K
Biogen$524
Sunovion Pharmaceuticals Inc.$350
UCB, Inc.$145
Novartis$107
Teva Pharmaceuticals USA, Inc.$46
plus $168 from 7 others

$27,584in research payments, 2019–2025

Across 3 payments — averaging $9194.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$28K

What the payments were for

Consulting fees$9,54925%
Speaking & faculty fees$23,69561%
Travel & lodging$2,9017%
Food & beverage$2,5227%
Education$530%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eisai Inc.	48	$37,381
Biogen	8	$524
Sunovion Pharmaceuticals Inc.	15	$350
UCB, Inc.	4	$145
Novartis	6	$107
Teva Pharmaceuticals USA, Inc.	2	$46
Avanir Pharmaceuticals, Inc.	2	$35
AstraZeneca	1	$29
AbbVie	2	$29
Boston Scientific	1	$21
Pfizer	1	$20
GE HealthCare	1	$19
Grifols USA, LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Leqembi$36,587

How this compares

$38,720 in reported general payments places this provider in the 95th percentile of 339 radiation oncology providers in Pennsylvania.

See all radiation oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$27,003

Medicare patients

193

Services billed

373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	11	$83,333
RexultiBrexpiprazole	12	$25,964
RytaryCarbidopa/Levodopa	30	$22,649
Carbidopa-LevodopaCarbidopa/Levodopa	114	$3,608
RivastigmineRivastigmine Tartrate	54	$3,568
Entacapone	23	$3,405
Rasagiline Mesylate	16	$2,442
Memantine Hcl	58	$1,584
Primidone	52	$1,175
Donepezil Hcl	106	$884
Memantine Hcl ErMemantine Hcl	14	$879
Carbidopa-Levodopa ErCarbidopa/Levodopa	20	$603
Gabapentin	17	$345
Pramipexole DihydrochloridePramipexole Di-Hcl	12	$335
Quetiapine Fumarate	11	$171

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Philadelphia

Neil TaunkPhiladelphia$203K
Wenyin ShiPhiladelphia$119K
Kevin NeadPhiladelphia$50K
Adam DickerPhiladelphia$46K
Bryan PukenasPhiladelphia$36K
Sameera KumarPhiladelphia$29K
Joshua MeyerPhiladelphia$25K
Abigail BermanPhiladelphia$25K
Michelle Alonso-BasantaPhiladelphia$23K
Andy MinnPhiladelphia$22K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →